- Gene editing developer Scribe plots an IPOThe California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go public in 2026.BioPharma Dive · 22d ago↗ source
- Novartis to acquire ADC developer in a deal worth up to $1.5BThe deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.BioPharma Dive · 22d ago↗ source
- Cancer, immune drugmakers dominate VC funding so far in 2026Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so far in 2026, per BioPharma Dive data.BioPharma Dive · 22d ago↗ source